Journal Article Review Ppublish 37 citations
PubMed: 36418600 DOI: 10.1007/s10787-022-01087-8
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Inflammopharmacology 31(1):1-7
Authors: Gaber El-Saber Batiha, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Mubarak Alruwaili, Raed AlRuwaili, Sarah M Albogami, Mohammed Alorabi, Hebatallah M Saad, Jesus Simal-Gandara
Affiliations
- Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AlBeheira, Egypt.
- Professor in department of clinical pharmacology and medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
- Department of Internal Medicine, College of Medicine, Jouf University, Sakaka, Saudi Arabia.
- Department of Biotechnology, College of Science, Taif University, P.O.Box 11099, Taif, 21944, Saudi Arabia.
- Department of Pathology, Faculty of Veterinary Medicine, Matrouh University, Marsa Matruh, 51744, Egypt.
- Nutrition and Bromatology Group, Department of Analytical Chemistry and Food Science, Faculty of Science, Universidade de Vigo, E-32004, Ourense, Spain.
Abstract
In coronavirus disease 2019 (Covid-19) era, neuroinflammation may develop due to neuronal tropism of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and/or associated immune activation, cytokine storm, and psychological stress. SARS-CoV-2 infection and linked cytokine storm may cause blood-brain barrier (BBB) injury through which activated immune cells and SARS-CoV-2 can pass into the brain causing activation of glial cells with subsequent neuroinflammation. Different therapeutic regimens were suggested to alleviate Covid-19-induced neuroinflammation. Since glibenclamide has anti-inflammatory and neuroprotective effects, it could be effective in mitigation of SARS-CoV-2 infection-induced neuroinflammation. Glibenclamide is a second-generation drug from the sulfonylurea family, which acts by inhibiting the adenosine triphosphate (ATP)-sensitive K channel in the regulatory subunit of type 1 sulfonylurea receptor (SUR-1) in pancreatic β cells. Glibenclamide reduces neuroinflammation and associated BBB injury by inhibiting the nod-like receptor pyrin 3 (NLRP3) inflammasome, oxidative stress, and microglial activation. Therefore, glibenclamide through inhibition of NLRP3 inflammasome, microglial activation, and oxidative stress may attenuate SARS-CoV-2-mediated neuroinflammation.
MeSH
Infections, Oxidative Stress, Stress, Physiological, Cells, Glyburide, Blood-Brain Barrier, Coronavirus, Weapons, Nlr Proteins, Covid-19, Sars-Cov-2
Cited by
- Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY). Future Virol, 2023
- Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions. Eur J Drug Metab Pharmacokinet, 2023
- SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway. Cell Stress Chaperones, 2023
- Neurological complications caused by SARS-CoV-2. Clin Microbiol Rev, 2024
- The effect of ramatroban on cytokine and thrombotic storms in Covid-19. Inflammopharmacology, 2023
- Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: the black side of the moon. Mol Cell Biochem, 2023
- New insight on the potential detrimental effect of metabolic syndrome on the Alzheimer disease neuropathology: Mechanistic role. J Cell Mol Med, 2024
- Hippo-YAP signaling and SARS-CoV-2 infection: a new mechanistic pathway. Cell Stress Chaperones, 2023
- Higher proinflammatory responses possibly contributing to suppressed cytotoxicity in patients with COVID-19 associated mucormycosis. Immunobiology, 2023
- Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases. Life Sci, 2023
- Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective. J Cell Mol Med, 2024
- Do K channels have a role in immunity? Front Immunol, 2024